NCT03532126已完成不适用
A Prospective, Multi-center, Non-comparative, 52-week Follow-up, Post-market Clinical Investigation of Princess® VOLUME PLUS Lidocaine in Subjects With Midface Volume Deficit
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 91
- 试验地点
- 4
- 主要终点
- Primary performance endpoint
研究概览
简要总结
This investigation aims to confirm the safety and effectiveness of Princess VOLUME PLUS Lidocaine in midface volume deficit augmentation and includes a long term safety followup.
详细描述
This non-interventional study will evaluate subjects treated with Princess VOLUME PLUS Lidocaine for midface volume deficit augmentation. A touch-up treatment will be allowed, on discretion of the treating investigator, if the initial treatment didn't provide optimal correction. The effectiveness parameters will be evaluated based on a validated scale for midface volume deficit scale and confirmed by use of patient reported outcome questionnaires as well as based on photographs to be evaluated by an independent evaluator.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18 years of age or older;
- •Presence of bilateral, approximately symmetric moderate to severe midface volume deficit, corresponding to MVDSS grades 2-3;
- •A negative urine pregnancy test at Visit 1 and commitment to use an adequate method of birth control for the duration of the clinical investigation (for women of childbearing potential only);
- •Healthy skin in the midface area and free of diseases that could interfere with evaluation of cutaneous aging or represent a risk for injection;
- •Willingness to abstain from any other aesthetic or surgical procedures in the treatment area for the duration of the investigation, including botulinum toxin injections (except glabella or forehead botulinum toxin treatment);
- •Capable to understand information about the investigation, including subjects' obligations, and is willing to take part, as evidenced by signed and dated informed consent.
排除标准
- •Presence or history of hypertrophic scarring, pigment disorders or keloid formation.
- •Presence or history of any autoimmune disease or current treatment with immune therapy.
- •History of hypersensitivity to hyaluronic acid, lidocaine hydrochloride or other amide-type local anaesthetics.
- •Previous treatment with a permanent filler in the area to be treated.
- •Pregnant or breastfeeding women.
- •Treatment with anticoagulants and platelet aggregation inhibitors (e.g., acetylsalicylic acid) within 10 days prior to Visit 1, unless the risk of bleeding/bruising is discharged after consultation with subject's physician who had prescribed such medicine.
- •Cutaneous, inflammatory and/or infectious processes (e.g., acne, herpes) in the area to be treated.
- •Laser therapy, dermabrasion or mesotherapy within 12 months, or chemical peeling within 3 months prior to Visit
- •History of other aesthetic/surgical treatment which may interfere with performance evaluation.
- •Current or previous (within 30 days of enrolment) treatment with another investigational drug and/or medical device or participation in another clinical study.
- •Previous enrolment in this clinical investigation.
- •Any person dependent on the investigator (e.g., employees, relatives, or similar), or employees of the investigation site institution or the Sponsor.
- •The following subjects shall not participate: persons with a legal custodian appointed due to mental disability, prisoners, soldiers and other members of the armed forces, civil servants (for Austria this is specified in the Medical Devices Act).
结局指标
主要结局
Primary performance endpoint
时间窗: 4 weeks
Response rate at week 4 based on investigator's midface volume deficit severity scale (MVDSS) assessment, where response is defined as a MVDSS grade improvement by ≥1 grade compared to baseline.
次要结局
- Secondary performance endpoint 2(4, 12, 24, 36 and 52 weeks)
- Secondary performance endpoint 6(4, 12, 24, 36 and 52 weeks)
- Secondary performance endpoint 1(12, 24, 36 and 52 weeks)
- Secondary performance endpoint 4(4, 12, 24, 36 and 52 weeks)
- Secondary performance endpoint 5(4, 12, 24, 36 and 52 weeks)
- Secondary performance endpoint 3(4, 12, 24, 36 and 52 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)Dermatological Non-DiseaseNCT03990883Croma-Pharma GmbH295
已完成
不适用
Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of Volume and Aesthetic Appearance of the Nose in Chinese AdultsNose EnhancementNCT03430986Allergan164
已完成
不适用
Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-FaceMid Face Volume LossNCT03754413Medy-Tox236
已完成
不适用
Neuramis® Volume Lidocaine Treatment in Patients With Loss of Mid-face VolumeAgingNCT02721368Medy-Tox88
已完成
不适用
Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and FoldsSkin WrinklingNCT01205048Galderma R&D171